200 related articles for article (PubMed ID: 11376267)
41. FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer.
Kitagawa Y; Sano K; Nishizawa S; Nakamura M; Ogasawara T; Sadato N; Yonekura Y
Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):63-71. PubMed ID: 12483411
[TBL] [Abstract][Full Text] [Related]
42. Comparison of MR imaging and FDG-PET/CT in the differential diagnosis of benign and malignant vertebral compression fractures.
Cho WI; Chang UK
J Neurosurg Spine; 2011 Feb; 14(2):177-83. PubMed ID: 21214309
[TBL] [Abstract][Full Text] [Related]
43. Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[1-11C]tyrosine PET.
Kole AC; Nieweg OE; Pruim J; Paans AM; Plukker JT; Hoekstra HJ; Schraffordt Koops H; Vaalburg W
J Nucl Med; 1997 May; 38(5):692-6. PubMed ID: 9170429
[TBL] [Abstract][Full Text] [Related]
44. Relationship between 18F-FDG uptake and breast density in women with normal breast tissue.
Vranjesevic D; Schiepers C; Silverman DH; Quon A; Villalpando J; Dahlbom M; Phelps ME; Czernin J
J Nucl Med; 2003 Aug; 44(8):1238-42. PubMed ID: 12902413
[TBL] [Abstract][Full Text] [Related]
45. 18FDG PET scanning of benign and malignant musculoskeletal lesions.
Feldman F; van Heertum R; Manos C
Skeletal Radiol; 2003 Apr; 32(4):201-8. PubMed ID: 12652335
[TBL] [Abstract][Full Text] [Related]
46. Imaging bone and soft tissue tumors with the proliferation marker [18F]fluorodeoxythymidine.
Buck AK; Herrmann K; Büschenfelde CM; Juweid ME; Bischoff M; Glatting G; Weirich G; Möller P; Wester HJ; Scheidhauer K; Dechow T; Peschel C; Schwaiger M; Reske SN
Clin Cancer Res; 2008 May; 14(10):2970-7. PubMed ID: 18445694
[TBL] [Abstract][Full Text] [Related]
47. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
[TBL] [Abstract][Full Text] [Related]
48. Standardized uptake value-based evaluations of solitary pulmonary nodules using F-18 fluorodeoxyglucose-PET/computed tomography.
Degirmenci B; Wilson D; Laymon CM; Becker C; Mason NS; Bencherif B; Agarwal A; Luketich J; Landreneau R; Avril N
Nucl Med Commun; 2008 Jul; 29(7):614-22. PubMed ID: 18528183
[TBL] [Abstract][Full Text] [Related]
49. Head and neck cancer: detection of recurrence with PET and 2-[F-18]fluoro-2-deoxy-D-glucose.
Lapela M; Grénman R; Kurki T; Joensuu H; Leskinen S; Lindholm P; Haaparanta M; Ruotsalainen U; Minn H
Radiology; 1995 Oct; 197(1):205-11. PubMed ID: 7568825
[TBL] [Abstract][Full Text] [Related]
50. Uterine tumors: pathophysiologic imaging with 16alpha-[18F]fluoro-17beta-estradiol and 18F fluorodeoxyglucose PET--initial experience.
Tsujikawa T; Yoshida Y; Mori T; Kurokawa T; Fujibayashi Y; Kotsuji F; Okazawa H
Radiology; 2008 Aug; 248(2):599-605. PubMed ID: 18539894
[TBL] [Abstract][Full Text] [Related]
51. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT.
Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E; Ebied O
Eur J Radiol; 2009 Jun; 70(3):530-8. PubMed ID: 18395387
[TBL] [Abstract][Full Text] [Related]
52. Normal FDG distribution patterns in the head and neck: PET/CT evaluation.
Nakamoto Y; Tatsumi M; Hammoud D; Cohade C; Osman MM; Wahl RL
Radiology; 2005 Mar; 234(3):879-85. PubMed ID: 15734938
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET.
Fukunaga T; Okazumi S; Koide Y; Isono K; Imazeki K
J Nucl Med; 1998 Jun; 39(6):1002-7. PubMed ID: 9627333
[TBL] [Abstract][Full Text] [Related]
54. Glucose metabolic analysis of musculoskeletal tumours using 18fluorine-FDG PET as an aid to preoperative planning.
Watanabe H; Shinozaki T; Yanagawa T; Aoki J; Tokunaga M; Inoue T; Endo K; Mohara S; Sano K; Takagishi K
J Bone Joint Surg Br; 2000 Jul; 82(5):760-7. PubMed ID: 10963181
[TBL] [Abstract][Full Text] [Related]
55. Comparison of MET-PET and FDG-PET for differentiation between benign lesions and malignant tumors of the lung.
Sasaki M; Kuwabara Y; Yoshida T; Nakagawa M; Koga H; Hayashi K; Kaneko K; Chen T; Ichiya Y; Masuda K
Ann Nucl Med; 2001 Oct; 15(5):425-31. PubMed ID: 11758947
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and Limitations of F-18-fluoro-2-deoxy-D-glucose Positron Emission Tomography to Differentiate Between Malignant and Benign Bone and Soft Tissue Tumors.
Miwa S; Mochizuki T; Yamamoto N; Shirai T; Hayashi K; Takeuchi A; Inatani H; Igarashi K; Higuchi T; Abe K; Taniguchi Y; Aiba H; Ikeda H; Tsuchiya H
Anticancer Res; 2018 Jul; 38(7):4065-4072. PubMed ID: 29970532
[TBL] [Abstract][Full Text] [Related]
57. Solitary brain lesions enhancing at MR imaging: evaluation with fluorine 18 fluorocholine PET.
Kwee SA; Ko JP; Jiang CS; Watters MR; Coel MN
Radiology; 2007 Aug; 244(2):557-65. PubMed ID: 17581887
[TBL] [Abstract][Full Text] [Related]
58. Nuclear imaging of bone tumors: FDG-PET.
Aoki J; Inoue T; Tomiyoshi K; Shinozaki T; Watanabe H; Takagishi K; Endo K
Semin Musculoskelet Radiol; 2001 Jun; 5(2):183-7. PubMed ID: 11500164
[TBL] [Abstract][Full Text] [Related]
59. Oncological diagnosis using (11)C-choline-positron emission tomography in comparison with 2-deoxy-2-[(18)F] fluoro-D-glucose-positron emission tomography.
Tian M; Zhang H; Higuchi T; Oriuchi N; Endo K
Mol Imaging Biol; 2004; 6(3):172-9. PubMed ID: 15193251
[TBL] [Abstract][Full Text] [Related]
60. F-18 FDG positron emission tomography and benign fractures.
Shon IH; Fogelman I
Clin Nucl Med; 2003 Mar; 28(3):171-5. PubMed ID: 12592121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
